ClinicalTrials.gg
CompletedNCT02606461SEALUpdated Jan 23, 2023Results posted

Selinexor in Advanced Liposarcoma

A Phase 2/3 interventional study of Selinexor and Placebo in Dedifferentiated Liposarcoma, sponsored by Karyopharm Therapeutics Inc. Completed at 71 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-01-23.

Sponsored by Karyopharm Therapeutics Inc · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Liposarcoma with a site in United States — 23 open to participants now, 36 under way, 5 of them phase 3. Liposarcoma · United States.

Enrollment
7th of 92
342 · median 44
Started
2016
with 4 others
Phase 2/3
3 of 101
none open now
Registered
44th of 101
by date

Among the 101 studies in Liposarcoma with a site in United States, this one is the 7th largest by enrollment of the 92 interventional ones that give a count, is one of 5 that started in 2016, is one of 3 in phase 2/3, and was the 44th registered.

Liposarcoma

160 studies on the registry are indexed under Liposarcoma; 36 are open to participants now.

Browse Liposarcoma studies →

Open to participants now

23 of the 101 studies in Liposarcoma with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Liposarcoma studies recruiting now, 20 (69%) set no upper age limit and 8 (28%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Liposarcoma with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).

Read the detailed description

In the Phase 2 portion of the study, 57 patients were randomized to selinexor (60 mg) or placebo at a 1:1 allocation ratio.

In the Phase 3 portion of the study, approximately 285 patients will be randomized to selinexor (60 mg) or placebo with a 2:1 allocation ratio.

Patients who progress during the blinded portion of the study will be unblinded and if receiving:

  • placebo, may cross over to open-label selinexor (60mg twice-weekly)
  • selinexor, will be withdrawn from further treatment and followed for survival

Study treatment will be given twice-weekly on Day 1 and Day 3 during Weeks 1-6 of each six-week (42 day) cycle until disease progression or intolerability.

Treatment will continue until one or more of the following occurs:

  • Disease progression, as defined by RECIST v1.1 Response Criteria
  • Clinical progression, as determined by the treating physician
  • Unacceptable adverse events (AEs) or failure to tolerate study treatment
  • Patient withdrawal
  • Patient discontinuation due to non-compliance
03

Conditions studied

  • Dedifferentiated Liposarcoma

Browse trials for

Keywords

  • Advanced unresectable dedifferentiated liposarcoma
  • selinexor
  • KCP-330
  • Karyopharm
  • Phase 2 / 3
  • dedifferentiated liposarcoma
  • Liposarcoma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥12 years of age
  2. Body surface area (BSA) ≥ 1.2 m2
  3. Histologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatment
  4. Must have per v1.1 Response Criteria
  5. Radiologic evidence of disease progression within 6 months prior to randomization. If the patient received other intervening therapy after documented disease progression, further disease progression must be documented after the completion of the intervening therapy
  6. Must have had at least 2 for liposarcoma (not to exceed 5 prior lines)
  7. If patient received any previous systemic therapy, the last dose must have been ≥ 21 days prior to randomization (or ≥ 5 half-lives of that drug, whichever is shorter) with all therapy-related toxicities having resolved to ≤ Grade 1

Exclusion criteria

Exclusion Criteria:

  1. Patients with pure well-differentiated liposarcoma (WDLS), myxoid/round cell or pleomorphic tumor histologic subtypes
  2. Known active (HepB), (HepC) or (HIV) infection
  3. Known central nervous system
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
342 participants (actual)

Study arms

  • Experimental
    Phase 2 Double-blinded: Selinexor

    Participants received a fixed blinding dose of 60 milligrams (mg) selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until progressive disease (PD).

    Drug: Selinexor

  • Experimental
    Phase 3 Double-blinded: Selinexor

    Participants received a fixed blinding dose of 60 mg selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD.

    Drug: Selinexor

  • Placebo comparator
    Phase 2 Double-blinded: Placebo Followed by Open Label- Selinexor

    Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD in double-blinded treatment period. Participants in the placebo group who had PD during the Phase 2 double-blinded treatment, will be elected to cross over to open-label selinexor.

    Drug: Placebo

  • Placebo comparator
    Phase 3 Double-blinded: Placebo Followed by Open Label- Selinexor

    Participants received a fixed blinding dose of placebo matched to selinexor twice-weekly on Day 1 and 3 during each 6-week (42-day) cycle until PD or development of unacceptable toxicity. Participants in the placebo group who had PD during the Phase 3 double-blinded treatment, will be elected to cross over to open-label selinexor.

    Drug: Placebo

Interventions

  • Selinexor 60mg

    Also known as: KPT-330

  • DrugPlacebo

    Also known as: sugar pill

06

What researchers measure

Primary outcomes

  1. Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)

  2. Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1

    PFS was defined as the time from the date of randomization in the Phase 3 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From the date of randomization in the Phase 3 open label period until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)

  3. Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1

    PFS was defined as the time from date of randomization until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)

  4. Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1

    PFS was defined as the time from date of randomization in the Phase 2 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From date of randomization in the Phase 2 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)

Secondary outcomes

  1. Phase 3 Double Blind: Overall Survival (OS)

    OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.

    Time frame: From date of randomization until death due to any cause, whichever occurred first (up to 70 months)

  2. Phase 3 Open Label: Overall Survival (OS)

    OS was defined as the duration (in months) from the date of randomization in the Phase 3 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.

    Time frame: From date of randomization in phase 3 open label period until death due to any cause, whichever occurred first (up to 70 months)

  3. Phase 2 Double Blind: Overall Survival (OS)

    OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.

    Time frame: From the date of randomization until death due to any cause, whichever occurred first (up to 70 months)

  4. Phase 2 Open Label: Overall Survival (OS)

    OS was defined as the duration (in months) from the date of randomization in the Phase 2 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.

    Time frame: From date of randomization in the Phase 2 open-label period until death due to any cause, whichever occurred first (up to 70 months)

  5. Phase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1

    TTP was defined as the time from date of randomization until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)

  6. Phase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1

    TTP was defined as the time from date of randomization in the Phase 3 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From date of randomization in the Phase 3 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)

  7. Phase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1

    TTP was defined as the time from date of randomization until ICR-determined PD as per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)

  8. Phase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1

    TTP was defined as the time from date of randomization in the Phase 2 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From date of randomization in the Phase 2 open-label period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)

  9. Phase 3 Double Blind: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR), per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of randomization until the documentation of CR or PR (up to 70 months)

  10. Phase 3 Open Label: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of randomization in the Phase 3 open label period until the documentation of CR or PR (up to 70 months)

  11. Phase 2 Double Blind: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of randomization until the documentation of CR or PR (up to 70 months)

  12. Phase 2 Open Label: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From date of randomization in the Phase 2 open-label period until the documentation of CR or PR (up to 70 months)

  13. Phase 3 Double Blind: Duration of Response (DOR)

    DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From first occurrence of CR or PR until the first date of PD (up to 70 months)

  14. Phase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment

    PFS was defined as the time from date of randomization until the first date of PD, per RECIST version 1.1, or death due to any cause as defined by the Investigator based on clinical and/or radiologic criteria. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 70 months)

  15. Phase 3 Double Blind: Time to Next Treatment (TTNT)

    TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.

    Time frame: Time from randomization to the first new antineoplastic therapy or death due to any cause (up to 70 months)

  16. Phase 2 Double Blind: Time to Next Treatment (TTNT)

    TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.

    Time frame: Time from randomization to the first new antineoplastic therapy or death due to any cause (up to 70 months)

  17. Phase 3 Double Blind: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

    Time frame: From start of study drug administration up to 70 months

  18. Phase 3 Open Label: Number of Participants With TEAEs and Serious TEAEs

    An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

    Time frame: From start of study drug administration up to 70 months

  19. Phase 2 Double Blind: Number of Participants With TEAEs and Serious TEAEs

    An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

    Time frame: From start of study drug administration up to 70 months

  20. Phase 2 Open Label: Number of Participants With TEAEs and Serious TEAEs

    An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

    Time frame: From start of study drug administration up to 70 months

  21. Phase 3 Double Blind: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)

    The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).

    Time frame: Baseline up to Day 1387

  22. Phase 3 Open Label: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)

    The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).

    Time frame: Baseline up to Day 379

07

Results

Posted Dec 7, 2021

Participant flow

The study was conducted at 71 sites in the United States, Canada, Germany, Belgium, Israel, United Kingdom, France, Spain, Italy, and Sweden. A total of 342 participants were enrolled, out of which 57 participants were randomized to receive study treatment in Phase 2 and 285 participants randomized, of which 284 participants received study treatment in Phase 3.

Period 1: Double-blinded Period
Participant flow — Period 1: Double-blinded Period
MilestonePhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: PlaceboPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: PlaceboPhase 2 Open-label: SelinexorPhase 3 Open-label: Selinexor
Started27301889700
Treated27301879700
Completed27301879700
Not completed001000
Withdrew: Randomized but no treatment001000
Period 2: Open Label Period
Participant flow — Period 2: Open Label Period
MilestonePhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: PlaceboPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: PlaceboPhase 2 Open-label: SelinexorPhase 3 Open-label: Selinexor
Started00002463
Completed00002463
Not completed000000

Outcome measures

PrimaryPhase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
Reported as:
Median · Months
Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
MonthsPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: Placebo
Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.12.83 (2.73 to 4.11)2.07 (1.51 to 3.06)
Statistical analysis
  • Phase 3 Double-blinded: Selinexor vs Phase 3 Double-blinded: Placebo · Log Rank · p = 0.0114 · Hazard ratio (hr): 0.7026 · 95% CI 0.5191 to 0.9509
PrimaryPhase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1

PFS was defined as the time from the date of randomization in the Phase 3 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From the date of randomization in the Phase 3 open label period until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
Reported as:
Median · Months
Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1
MonthsPhase 3 Open Label: Selinexor
Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.12.73 (1.97 to 4.14)
PrimaryPhase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1

PFS was defined as the time from date of randomization until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
Reported as:
Median · Months
Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1
MonthsPhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: Placebo
Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.13.02 (1.41 to NA)2.76 (1.58 to NA)
Statistical analysis
  • Phase 2 Double-blinded: Selinexor vs Phase 2 Double-blinded: Placebo · Log Rank · p = 0.6051 · Hazard ratio, log: 1.1521 · 95% CI 0.5357 to 2.4778
PrimaryPhase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1

PFS was defined as the time from date of randomization in the Phase 2 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From date of randomization in the Phase 2 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
Reported as:
Median · Months
Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1
MonthsPhase 2 Open Label: Selinexor
Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.11.38 (1.38 to 2.27)
SecondaryPhase 3 Double Blind: Overall Survival (OS)

OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.

Time frame:
From date of randomization until death due to any cause, whichever occurred first (up to 70 months)
Reported as:
Median · Months
Phase 3 Double Blind: Overall Survival (OS)
MonthsPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: Placebo
Phase 3 Double Blind: Overall Survival (OS)10.38 (8.41 to 13.40)12.71 (8.54 to 15.90)
SecondaryPhase 3 Open Label: Overall Survival (OS)

OS was defined as the duration (in months) from the date of randomization in the Phase 3 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.

Time frame:
From date of randomization in phase 3 open label period until death due to any cause, whichever occurred first (up to 70 months)
Reported as:
Median · Months
Phase 3 Open Label: Overall Survival (OS)
MonthsPhase 3 Open Label: Selinexor
Phase 3 Open Label: Overall Survival (OS)10.18 (5.78 to 14.69)
SecondaryPhase 2 Double Blind: Overall Survival (OS)

OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.

Time frame:
From the date of randomization until death due to any cause, whichever occurred first (up to 70 months)
Reported as:
Median · Months
Phase 2 Double Blind: Overall Survival (OS)
MonthsPhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: Placebo
Phase 2 Double Blind: Overall Survival (OS)17.31 (10.51 to 29.57)16.07 (8.38 to 23.06)
SecondaryPhase 2 Open Label: Overall Survival (OS)

OS was defined as the duration (in months) from the date of randomization in the Phase 2 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier.

Time frame:
From date of randomization in the Phase 2 open-label period until death due to any cause, whichever occurred first (up to 70 months)
Reported as:
Median · Months
Phase 2 Open Label: Overall Survival (OS)
MonthsPhase 2 Open Label: Selinexor
Phase 2 Open Label: Overall Survival (OS)8.90 (4.96 to 18.92)
SecondaryPhase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1

TTP was defined as the time from date of randomization until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)
Reported as:
Median · Months
Phase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1
MonthsPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: Placebo
Phase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.12.83 (2.73 to 4.11)2.10 (1.51 to 3.06)
SecondaryPhase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1

TTP was defined as the time from date of randomization in the Phase 3 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From date of randomization in the Phase 3 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)
Reported as:
Median · Months
Phase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1
MonthsPhase 3 Open Label: Selinexor
Phase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.12.73 (1.97 to 4.14)
SecondaryPhase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1

TTP was defined as the time from date of randomization until ICR-determined PD as per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)
Reported as:
Median · Months
Phase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1
MonthsPhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: Placebo
Phase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.13.02 (1.41 to NA)2.76 (1.58 to NA)
SecondaryPhase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1

TTP was defined as the time from date of randomization in the Phase 2 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From date of randomization in the Phase 2 open-label period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)
Reported as:
Median · Months
Phase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1
MonthsPhase 2 Open Label: Selinexor
Phase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.11.38 (1.38 to 2.27)
SecondaryPhase 3 Double Blind: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR), per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of randomization until the documentation of CR or PR (up to 70 months)
Reported as:
Number · Percentage of participants
Phase 3 Double Blind: Overall Response Rate (ORR)
Percentage of participantsPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: Placebo
Phase 3 Double Blind: Overall Response Rate (ORR)2.7 (0.9 to 6.1)0 (NA to NA)
SecondaryPhase 3 Open Label: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of randomization in the Phase 3 open label period until the documentation of CR or PR (up to 70 months)
Reported as:
Number · Percentage of participants
Phase 3 Open Label: Overall Response Rate (ORR)
Percentage of participantsPhase 3 Open Label: Selinexor
Phase 3 Open Label: Overall Response Rate (ORR)3.2 (0.4 to 11)
SecondaryPhase 2 Double Blind: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of randomization until the documentation of CR or PR (up to 70 months)
Reported as:
Number · Percentage of participants
Phase 2 Double Blind: Overall Response Rate (ORR)
Percentage of participantsPhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: Placebo
Phase 2 Double Blind: Overall Response Rate (ORR)0 (NA to NA)0 (NA to NA)
SecondaryPhase 2 Open Label: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From date of randomization in the Phase 2 open-label period until the documentation of CR or PR (up to 70 months)
Reported as:
Number · Percentage of participants
Phase 2 Open Label: Overall Response Rate (ORR)
Percentage of participantsPhase 2 Open Label: Selinexor
Participants who achieved CR0
Participants who achieved PR0
SecondaryPhase 3 Double Blind: Duration of Response (DOR)

DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From first occurrence of CR or PR until the first date of PD (up to 70 months)
Reported as:
Number · Months
Phase 3 Double Blind: Duration of Response (DOR)
MonthsPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: Placebo
Phase 3 Double Blind: Duration of Response (DOR)7.39 (NA to NA)—
SecondaryPhase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment

PFS was defined as the time from date of randomization until the first date of PD, per RECIST version 1.1, or death due to any cause as defined by the Investigator based on clinical and/or radiologic criteria. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 70 months)
Reported as:
Median · Months
Phase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment
MonthsPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: Placebo
Phase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment2.89 (2.76 to 4.17)1.87 (1.45 to 2.89)
SecondaryPhase 3 Double Blind: Time to Next Treatment (TTNT)

TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.

Time frame:
Time from randomization to the first new antineoplastic therapy or death due to any cause (up to 70 months)
Reported as:
Median · Months
Phase 3 Double Blind: Time to Next Treatment (TTNT)
MonthsPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: Placebo
Phase 3 Double Blind: Time to Next Treatment (TTNT)5.42 (4.67 to 6.34)3.22 (2.56 to 3.78)
SecondaryPhase 2 Double Blind: Time to Next Treatment (TTNT)

TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first.

Time frame:
Time from randomization to the first new antineoplastic therapy or death due to any cause (up to 70 months)
Reported as:
Median · Months
Phase 2 Double Blind: Time to Next Treatment (TTNT)
MonthsPhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: Placebo
Phase 2 Double Blind: Time to Next Treatment (TTNT)4.96 (3.91 to 14.03)2.92 (2.04 to 5.06)
SecondaryPhase 3 Double Blind: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

Time frame:
From start of study drug administration up to 70 months
Reported as:
Count of participants · Participants
Phase 3 Double Blind: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: Placebo
Participants with TEAEs18794
Participants with Serious TEAEs7318
SecondaryPhase 3 Open Label: Number of Participants With TEAEs and Serious TEAEs

An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

Time frame:
From start of study drug administration up to 70 months
Reported as:
Count of participants · Participants
Phase 3 Open Label: Number of Participants With TEAEs and Serious TEAEs
ParticipantsPhase 3 Open Label: Selinexor
Participants with TEAEs63
Participants with Serious TEAEs25
SecondaryPhase 2 Double Blind: Number of Participants With TEAEs and Serious TEAEs

An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

Time frame:
From start of study drug administration up to 70 months
Reported as:
Count of participants · Participants
Phase 2 Double Blind: Number of Participants With TEAEs and Serious TEAEs
ParticipantsPhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: Placebo
Participants with TEAEs2729
Participants with Serious TEAEs46
SecondaryPhase 2 Open Label: Number of Participants With TEAEs and Serious TEAEs

An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

Time frame:
From start of study drug administration up to 70 months
Reported as:
Count of participants · Participants
Phase 2 Open Label: Number of Participants With TEAEs and Serious TEAEs
ParticipantsPhase 2 Open Label: Selinexor
Participants with TEAEs24
Participants with Serious TEAEs13
SecondaryPhase 3 Double Blind: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)

The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).

Time frame:
Baseline up to Day 1387
Reported as:
Mean · Score on a Scale
Phase 3 Double Blind: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)
Score on a ScalePhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: Placebo
Global Health Status33.33 ± NA—
Physical Functioning20.00 ± NA—
Role Functioning16.67 ± NA—
Emotional Functioning8.33 ± NA—
Social Functioning50.00 ± NA—
Cognitive Functioning0.00 ± NA—
Fatigue-22.22 ± NA—
Nausea and Vomiting16.67 ± NA—
Pain0.00 ± NA—
Dyspnoea0.00 ± NA—
Insomnia33.33 ± NA—
Appetite Loss0.00 ± NA—
Constipation0.00 ± NA—
Diarrhoea33.33 ± NA—
Financial Difficulties-66.67 ± NA—
SecondaryPhase 3 Open Label: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)

The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status).

Time frame:
Baseline up to Day 379
Reported as:
Mean · Score on a Scale
Phase 3 Open Label: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30)
Score on a ScalePhase 3 Open Label: Selinexor
Global Health Status-16.67 ± NA
Physical Functioning-40.00 ± NA
Role Functioning-33.33 ± NA
Emotional Functioning0.00 ± NA
Social Functioning-50.00 ± NA
Cognitive Functioning-16.67 ± NA
Fatigue66.67 ± NA
Nausea and Vomiting0.00 ± NA
Pain0.00 ± NA
Dyspnoea0.00 ± NA
Insomnia0.00 ± NA
Appetite Loss0.00 ± NA
Constipation0.00 ± NA
Diarrhoea0.00 ± NA
Financial Difficulties100.00 ± NA

Adverse events

Collected over From start of study drug administration up to 70 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 2 Double-blinded: Selinexor18/27 (66.7%)4/27 (14.8%)27/27 (100%)
Phase 2 Double-blinded: Placebo25/30 (83.3%)6/30 (20%)29/30 (96.7%)
Phase 3 Double-blinded: Selinexor127/187 (67.9%)73/187 (39%)186/187 (99.5%)
Phase 3 Double-blinded: Placebo67/97 (69.1%)18/97 (18.6%)94/97 (96.9%)
Phase 2 Open-label: Selinexor20/24 (83.3%)13/24 (54.2%)24/24 (100%)
Phase 3 Open-label: Selinexor43/63 (68.3%)25/63 (39.7%)62/63 (98.4%)
Most frequent serious events
Showing 10 of 109
Most frequent serious events
EventPhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: PlaceboPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: PlaceboPhase 2 Open-label: SelinexorPhase 3 Open-label: Selinexor
NauseaGastrointestinal disorders0/270/304/1870/973/240/63
Small intestine obstructionGastrointestinal disorders0/271/302/1872/972/242/63
VomitingGastrointestinal disorders0/270/302/1871/972/240/63
PneumoniaInfections and infestations0/272/303/1870/972/241/63
HypoxiaRespiratory, thoracic and mediastinal disorders0/270/300/1870/972/240/63
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/270/302/1871/970/243/63
AnaemiaBlood and lymphatic system disorders1/270/303/1870/971/242/63
Cardiac arrestCardiac disorders0/270/300/1870/971/240/63
Large intestine perforationGastrointestinal disorders0/271/300/1870/971/240/63
StomatitisGastrointestinal disorders0/270/300/1870/971/240/63
Most frequent other events
Showing 10 of 90
Most frequent other events
EventPhase 2 Double-blinded: SelinexorPhase 2 Double-blinded: PlaceboPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: PlaceboPhase 2 Open-label: SelinexorPhase 3 Open-label: Selinexor
NauseaGastrointestinal disorders24/2710/30151/18738/9720/2445/63
Decreased appetiteMetabolism and nutrition disorders15/275/30144/18721/9714/2432/63
FatigueGeneral disorders15/2714/3096/18731/9718/2433/63
Weight decreasedInvestigations14/270/3081/1879/9715/2425/63
AnaemiaBlood and lymphatic system disorders16/279/3091/18722/9710/2426/63
VomitingGastrointestinal disorders15/274/3093/18712/9714/2431/63
ThrombocytopeniaBlood and lymphatic system disorders11/272/3072/1875/9711/2424/63
HyponatraemiaMetabolism and nutrition disorders9/276/3052/1878/9710/2411/63
DiarrhoeaGastrointestinal disorders8/275/3075/18717/977/2418/63
ConstipationGastrointestinal disorders6/278/3074/18723/976/2414/63

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 2 Double-blinded: SelinexorPhase 2 Double-blinded: PlaceboPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: PlaceboTotal
<=18 years00000
Between 18 and 65 years19179246174
>=65 years8139651168
Sex: Female, Male
Sex: Female, Male(Participants)Phase 2 Double-blinded: SelinexorPhase 2 Double-blinded: PlaceboPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: PlaceboTotal
Female12117433130
Male151911464212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 2 Double-blinded: SelinexorPhase 2 Double-blinded: PlaceboPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: PlaceboTotal
Hispanic or Latino237618
Not Hispanic or Latino252514979278
Unknown or Not Reported02321246
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 2 Double-blinded: SelinexorPhase 2 Double-blinded: PlaceboPhase 3 Double-blinded: SelinexorPhase 3 Double-blinded: PlaceboTotal
American Indian or Alaska Native00000
Asian259319
Native Hawaiian or Other Pacific Islander10203
Black or African American12317
White232013980262
More than one race03341350
Unknown or Not Reported00101
08

Study locations

71 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Stanford University
    Stanford, California 94305, United States
  • University of Colorado-Denver
    Denver, Colorado 80202, United States
  • Yale Cancer Center
    New Haven, Connecticut 06520-8032, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Northwell Health Physicians Partners
    New York, New York 11042, United States
  • Duke Institute of Cancer
    Durham, North Carolina 27710, United States
  • James Cancer Center, Ohio State University
    Columbus, Ohio 43210-1240, United States
  • Oregon Health and Science
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19106, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • University of Pittsburgh Medical Center (UPMC)
    Pittsburgh, Pennsylvania 15232, United States
  • Vanderbilt
    Nashville, Tennessee 37232, United States
  • MD Anderson
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • UZ Brussel
    Brussels, 1090, Belgium
  • UCL Saint-Luc
    Brussels, 1200, Belgium
  • UZ Gent
    Ghent, 9000, Belgium
  • Cross Cancer Center - Alberta Health Services
    Edmonton, Alberta T6G1Z2, Canada
  • The Ottawa Hospital Cancer
    Ottawa, Ontario, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • McGill University
    Montréal, Quebec H4A3J1, Canada
  • Institut Bergonie
    Bordeaux,, 33076, France
  • Oscar Lambret Center
    Lille Cedex 307, 59020, France
  • Centre Leon Berard
    Lyon Cedex, 96373, France
  • Timone University Hospital
    Marseille Cedex 5, 13385, France
  • Institut Régional du Cancer de Montpellier (ICM)
    Montpellier, 34298, France
  • CLCC Antoine Lacassagne
    Nice, 06789, France
  • Institut Curie
    Paris, 75248, France
  • Institut Claudius Regaud
    Toulouse, 31059, France
  • Institut Gustave Roussy
    Villejuif, 94110, France
  • Helios Hospital Berlin-Buch
    Berlin, 13125, Germany
  • Technische Universitaet Dresden Med. Fakultaet Carl Gustav Carus Med. Klinik u. Poliklinik I
    Dresden, 01307, Germany
  • National Center for Tumor Diseases, Univeristy Hospital Heidelberg
    Heidelberg, 69120, Germany
  • University Hospital Mannheim
    Mannheim, 68167, Germany
  • Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie Klinikum rechts der Isar der TU Muenchen
    Muenchen, 81675, Germany
  • Soroka University Medical Center
    Be'er Sheva, 84101, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Rabin Medical Center
    Petach Tikva, 4941492, Israel
  • Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Tel Aviv Sourasky Medical
    Tel Aviv, 64239, Israel
  • Assaf Harofe Medical Center
    Zerifin, 7030000, Israel
  • Candiolo Cancer Institute
    Candiolo, 10060, Italy
  • Istituto Nazionale dei Tumori, Milan
    Milano, 20133, Italy
  • U.O.C. Oncologia Medica Oncology Department
    Palermo, 90127, Italy
  • Policlinico Universitario Campus Biomedico
    Roma, 00128, Italy
  • "Germans Trias Pujol" University Hospital
    Badalona, 41013, Spain
  • Vall d´hebron University Hospital
    Barcelona, 08035, Spain
  • Hospital Sant Pau Barcelona
    Barcelona, 08041, Spain
  • Hospital ICO Bellvitge
    Barcelona, 08908, Spain
  • Hospital Universitario Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, 41013, Spain
  • Hospital La Fe Valencia
    Valencia, 46026, Spain
  • Sahlgrenska Universitetssjukhuset
    Göteborg, 413 45, Sweden
  • Skane University Hospital
    Lund, 221 85, Sweden
  • Onkologiska Kliniken
    Stockholm, 171 76, Sweden
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, CB2 0QQ, United Kingdom
  • University College London Hospitals
    London, NW1 2BU, United Kingdom
  • The Royal Marsden NHS Foundation Trust
    London, SW3 6JJ, United Kingdom
  • The Christie
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Groschel S, Hatcher H, Duffaud F, Herraez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Gotze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 Aug 1;40(22):2479-2490. doi: 10.1200/JCO.21.01829. Epub 2022 Apr 8. PubMed 35394800 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Oct 2020, 57 months.

Results were first posted in Dec 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2015
First posted
Nov 17, 2015
StartActual
Jan 4, 2016
Primary completionActual
Oct 28, 2020
CompletionActual
Oct 26, 2021
Results first posted
Dec 7, 2021
Last update
Jan 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02606461
Responsible party
Sponsor
First posted
Nov 17, 2015
Start date
Jan 4, 2016
Primary completion
Oct 28, 2020
Completion
Oct 26, 2021
Results posted
Dec 7, 2021
Last update
Jan 23, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion